Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTS2711
- Development stage
- Preclinical
- Lead developer
- CytosinLab
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
CTS2711 is an investigational DNA-modulating agent developed by CytosinLab, specifically targeting solid tumors with TP53 deletions or mutations. While the precise molecular mechanism of action remains undisclosed, the drug is designed to exploit the genetic vulnerabilities of p53-deficient cancer cells through DNA modulation. It represents part of CytosinLab's broader portfolio focused on epigenetic therapies and DNA-targeted interventions for high-need oncological indications.
Beyond the preview
Go deeper on CTS2711.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTS2711.